111 related articles for article (PubMed ID: 1676166)
1. CY 208-243 behaves as a typical D-1 agonist in the reserpine-treated mouse.
Abbott B; Starr BS; Starr MS
Pharmacol Biochem Behav; 1991 Feb; 38(2):259-63. PubMed ID: 1676166
[TBL] [Abstract][Full Text] [Related]
2. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
Starr BS; Starr MS; Kilpatrick IC
Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
[TBL] [Abstract][Full Text] [Related]
3. Motor depression: a new role for D1 receptors?
Chandler CJ; Wohab W; Starr BS; Starr MS
Neuroscience; 1990; 38(2):437-45. PubMed ID: 2148204
[TBL] [Abstract][Full Text] [Related]
4. Behavioural interactions involving D1 and D2 dopamine receptors in non-habituated mice.
Starr BS; Starr MS
Neuropharmacology; 1987 Jun; 26(6):613-9. PubMed ID: 2955244
[TBL] [Abstract][Full Text] [Related]
5. New putative selective agonists at the D-1 dopamine receptor: behavioural and neurochemical comparison of CY 208-243 with SK&F 101384 and SK&F 103243.
Murray AM; Waddington JL
Pharmacol Biochem Behav; 1990 Jan; 35(1):105-10. PubMed ID: 1969161
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Implications for the roles of D1 and D2 receptors.
Starr BS; Starr MS
Neuropharmacology; 1986 May; 25(5):455-63. PubMed ID: 3488514
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse.
Starr MS; Starr BS
Eur J Pharmacol; 1993 Dec; 250(2):239-46. PubMed ID: 7906652
[TBL] [Abstract][Full Text] [Related]
8. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants.
Serra G; Collu M; D'Aquila PS; De Montis GM; Gessa GL
Brain Res; 1990 Sep; 527(2):234-43. PubMed ID: 1979237
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat.
Damsma G; Tham CS; Robertson GS; Fibiger HC
Eur J Pharmacol; 1990 Sep; 186(2-3):335-8. PubMed ID: 1981190
[TBL] [Abstract][Full Text] [Related]
10. Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors.
Starr MS; Starr BS
Eur J Pharmacol; 1995 Apr; 277(2-3):151-8. PubMed ID: 7493603
[TBL] [Abstract][Full Text] [Related]
11. Grooming in the mouse is stimulated by the dopamine D1 agonist SKF 38393 and by low doses of the D1 antagonist SCH 23390, but is inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390.
Starr BS; Starr MS
Pharmacol Biochem Behav; 1986 Apr; 24(4):837-9. PubMed ID: 2940604
[TBL] [Abstract][Full Text] [Related]
12. Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.
Ross SB; Jackson DM; Wallis EM; Edwards SR
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):512-8. PubMed ID: 3261844
[TBL] [Abstract][Full Text] [Related]
13. Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801.
Goodwin P; Starr BS; Starr MS
J Neural Transm Park Dis Dement Sect; 1992; 4(1):15-26. PubMed ID: 1531757
[TBL] [Abstract][Full Text] [Related]
14. Combination of a delta opioid receptor agonist but not a mu opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice.
Toyoshi T; Ukai M; Kameyama T
Eur J Pharmacol; 1992 Mar; 213(1):25-30. PubMed ID: 1354161
[TBL] [Abstract][Full Text] [Related]
15. Opposite effects of stimulation of D1 and D2 dopamine receptors on the expression of motor seizures in mouse and rat.
al-Tajir G; Chandler CJ; Starr BS; Starr MS
Neuropharmacology; 1990 Jul; 29(7):657-61. PubMed ID: 1974713
[TBL] [Abstract][Full Text] [Related]
16. Dynorphin A(1-13) preferentially inhibits behaviors induced by the D2 dopamine agonist RU 24213 but not by the D1 dopamine agonist SK&F 38393.
Ukai M; Toyoshi T; Kameyama T
Pharmacol Biochem Behav; 1992 Aug; 42(4):755-9. PubMed ID: 1355296
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors.
Vasse M; Protais P
Neuropharmacology; 1989 Sep; 28(9):931-9. PubMed ID: 2554186
[TBL] [Abstract][Full Text] [Related]
18. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD
Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118
[TBL] [Abstract][Full Text] [Related]
19. In morphinised rats SKF 38393 converts dopamine D2 receptor-mediated forward locomotion into backward walking.
Axon DI; Fletcher GH; Starr MS
Pharmacol Biochem Behav; 1987 Jan; 26(1):45-7. PubMed ID: 3494255
[TBL] [Abstract][Full Text] [Related]
20. Behavioural synergism between the dopamine agonists SKF 38393 and LY 171555 in dopamine-depleted mice: antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors.
Starr MS; Starr BS
Pharmacol Biochem Behav; 1989 May; 33(1):41-4. PubMed ID: 2571171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
